Summary & Overview
HCPCS J2372: Phenylephrine Hydrochloride Injection, 20 mcg
HCPCS Level II code J2372 denotes a 20 microgram injection of phenylephrine hydrochloride (biorphen), a vasoconstrictor used to support blood pressure in acute care settings. This billing code is relevant nationally for facilities and clinicians that administer injectable vasoactive medications, particularly in hospitals, emergency departments, and procedural suites.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose, typical sites of service, and the payer landscape covered. The publication provides benchmarks and coding context where available, highlights any recent policy or coverage considerations affecting use of injectable phenylephrine products, and summarizes common billing practices tied to administration of vasoactive agents.
The report is intended to help billing professionals, clinical coders, and policy analysts understand how J2372 is used in practice, what payers commonly consider in coverage, and where to look for further policy details. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2372 represents an injection of phenylephrine hydrochloride (biorphen), 20 micrograms. This code describes a pharmaceutical administration service involving a vasoconstrictor agent delivered by injection.
Service Type: Drug administration (injectable vasoactive agent)
Typical Site of Service: Hospital inpatient or outpatient settings, emergency department, and other acute care settings where injectable vasopressors are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old undergoing an ophthalmology procedure such as cataract extraction or intravitreal injection requiring short-acting topical or intraocular vasoconstriction. The clinician prepares and administers J2372 (phenylephrine hydrochloride, 20 micrograms) as an intraocular or periocular injection to achieve pupillary dilation and hemostasis during the procedure. The clinical workflow includes pre-procedure verification of medication, informed consent for intraocular medication, verification of allergies and cardiovascular history, sterile preparation, administration by the ophthalmic surgeon or authorized proceduralist in the ambulatory surgical center or operating room, and post-administration monitoring for hypertension, reflex bradycardia, or local ocular irritation. Documentation includes medication lot number, dose (20 micrograms), route, time of administration, clinician taxonomy, and any immediate adverse events. Typical sites of service are ambulatory surgical center (ASC), hospital outpatient department, and physician office-based procedure rooms where ophthalmic surgeries are performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstance applies to the administration of . |